Clinical Trial Update: A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing accelerated infusion rate of daratumumab in relapsed and refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Canadian Myeloma Research Group | Conditions: Multiple Myeloma in Relapse | Phase 2 | Status: COMPLETED